Skip to content

P.H.A.: what changed

Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

P.H.A.

BE 0804.582.039
NACE 47.730, Retail sale of pharmaceutical products
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
€5,743
2024 · €22,297-€16,554
Equity
€52,269
2024 · €46,527+€5,743
Cash
€44,211
2024 · €33,542+€10,669
Balance sheet total
€60,047
2024 · €49,461+€10,586

Largest movements

2024 to 2025
Assets
  • Cash +€10,669

    up €10,669 (+31.8%), from €33,542 to €44,211

    mainly Net result for the year (+€5,743) and Tax, wage and social debts (+€4,697)

Equity and liabilities
  • Profit (loss) carried forward +€5,743

    up €5,743 (+13.2%), from €43,527 to €49,269

  • Tax, wage and social debts +€4,697

    up €4,697 (+162.6%), from €2,888 to €7,584

Income statement
  • Taxes +€12,417

    new in 2025: €12,417

  • Gross operating margin -€3,896

    down €3,896 (-17.4%), from €22,340 to €18,445

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 €22,297
Gross operating margin -€3,896
Other operating charges -€60
Financial charges -€182
Taxes -€12,417
Result 2025 €5,743

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations +€10,669
Investment €0
Financing €0
Cash 2024 €33,542
Net result for the year +€5,743
Receivables within one year +€202
Deferred charges and accrued income -€119
Trade debts +€147
Tax, wage and social debts +€4,697
Cash 2025 €44,211
Every line side by side 26 lines
Line Code 2024 2025 Change %
Total assets 20/58 €49,461 €60,047 +€10,586 +21.4%
Current assets 29/58 €49,461 €60,047 +€10,586 +21.4%
Amounts receivable within one year 40/41 €15,877 €15,676 -€202 -1.3%
Trade receivables 40 €14,427 €13,779 -€648 -4.5%
Other amounts receivable 41 €1,450 €1,896 +€446 +30.8%
Cash at bank and in hand 54/58 €33,542 €44,211 +€10,669 +31.8%
Deferred charges and accrued income 490/1 €41 €160 +€119 +289.5%
Total equity and liabilities 10/49 €49,461 €60,047 +€10,586 +21.4%
Equity 10/15 €46,527 €52,269 +€5,743 +12.3%
Contributions 10/11 €3,000 €3,000 = 0.0%
Profit (loss) carried forward 14 €43,527 €49,269 +€5,743 +13.2%
Amounts payable 17/49 €2,934 €7,778 +€4,844 +165.1%
Amounts payable within one year 42/48 €2,934 €7,778 +€4,844 +165.1%
Trade debts 44 €46 €194 +€147 +318.2%
Suppliers 440/4 €46 €194 +€147 +318.2%
Taxes, remuneration and social security 45 €2,888 €7,584 +€4,697 +162.6%
Taxes 450/3 €2,888 €7,584 +€4,697 +162.6%
Other operating charges 640/8 - €60 +€60
Gross operating margin 9900 €22,340 €18,445 -€3,896 -17.4%
Operating profit (loss) 9901 €22,340 €18,385 -€3,956 -17.7%
Financial charges 65/66B €44 €226 +€182 +418.8%
Recurring financial charges 65 €44 €226 +€182 +418.8%
Profit (loss) for the period before taxes 9903 €22,297 €18,159 -€4,138 -18.6%
Income taxes 67/77 - €12,417 +€12,417
Profit (loss) for the period 9904 €22,297 €5,743 -€16,554 -74.2%
Profit (loss) for the period to be appropriated 9905 €22,297 €5,743 -€16,554 -74.2%

Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 1 October 2026 via checked.be.